{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:25:56Z","timestamp":1777555556659,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T00:00:00Z","timestamp":1445817600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s40360-015-0026-9","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T22:59:03Z","timestamp":1445900343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A novel nasal powder formulation of glucagon: toxicology studies in animal models"],"prefix":"10.1186","volume":"16","author":[{"given":"Frederick E.","family":"Reno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Normand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"McInally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherwin","family":"Silo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Stotland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam","family":"Triest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Carballo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Pich\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,26]]},"reference":[{"key":"26_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00125-002-0822-9","volume":"45","author":"PE Cryer","year":"2002","unstructured":"Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II Diabetes. Diabetologia. 2002;45:937\u201348.","journal-title":"Diabetologia"},{"key":"26_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/9780470516270.ch2","volume-title":"Hypoglycaemia in clinical diabetes","author":"IJ Deary","year":"2007","unstructured":"Deary IJ. Symptoms of hypoglycaemia and effects on mental performance and emotions. In: Frier BM, Fisher M, editors. Hypoglycaemia in clinical diabetes. 2nd ed. Chicester, West Sussex, England: John Wiley & Sons Limited; 2007. p. 25\u201348.","edition":"2"},{"key":"26_CR3","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.2337\/diacare.26.6.1902","volume":"26","author":"PE Cryer","year":"2003","unstructured":"Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902\u201312.","journal-title":"Diabetes Care"},{"key":"26_CR4","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2337\/diacare.28.6.1333","volume":"28","author":"AM Leckie","year":"2005","unstructured":"Leckie AM, Graham MK, Grant JB, Ritchie PJ, Frier BM. Frequency, severity, and morbidity of hypoglycemia occurring in the workplace in people with insulin-treated diabetes. Diabetes Care. 2005;28:1333\u20138.","journal-title":"Diabetes Care"},{"key":"26_CR5","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.2337\/diacare.28.12.2948","volume":"28","author":"NN Zammitt","year":"2005","unstructured":"Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28:2948\u201361.","journal-title":"Diabetes Care"},{"key":"26_CR6","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s00125-007-0599-y","volume":"50","author":"UK Hypoglycemia Study Group","year":"2007","unstructured":"UK Hypoglycemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140\u20137.","journal-title":"Diabetologia"},{"key":"26_CR7","first-page":"1","volume-title":"Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention","author":"PE Cryer","year":"2009","unstructured":"Cryer PE. The clinical problem of hypoglycemia in diabetes. In: Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention. Alexandria, VA: American Diabetes Association; 2009. p. 1\u201315."},{"issue":"suppl 1","key":"26_CR8","first-page":"S1","volume":"38","author":"American Diabetes Association","year":"2015","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142015. Diabetes Care. 2015;38 suppl 1:S1\u201394.","journal-title":"Diabetes Care"},{"key":"26_CR9","first-page":"10","volume-title":"Introduction to biological membranes","author":"MK Jain","year":"1988","unstructured":"Jain MK. Components of biological membranes. In: Introduction to biological membranes. New York: John Wiley & Sons; 1988. p. 10\u201350."},{"key":"26_CR10","unstructured":"GLUCACON (glucagon for injection, rDNA origin) Product Monograph. Toronto, Ontario: Eli Lilly Canada Inc.; 2012 http:\/\/www.lilly.ca\/en\/pdf\/product-monograph\/04_rglucagon-pm_9july2012.pdf . Accessed 26 September 2015."},{"key":"26_CR11","unstructured":"GLUCAGEN\u00ae and GLUCAGEN\u00ae Hypokit 1\u00a0mg (glucagon) Product Monograph. Mississauga, Ontario: Novo Nordisk Canada Inc.; 2014. http:\/\/www.paladin-labs.com\/our_products\/PM_GlucaGen_EN.pdf . Accessed 26 September 2015."},{"key":"26_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3181\/00379727-85-20934","volume":"85","author":"MA Root","year":"1954","unstructured":"Root MA, Ellis J, Staub A. Effect of glucagon on insulin hypoglycemia. Proc Soc Exp Biol Med. 1954;85:507\u201311.","journal-title":"Proc Soc Exp Biol Med"},{"key":"26_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1600-0773.1993.tb01544.x","volume":"73","author":"C Eistrup","year":"1993","unstructured":"Eistrup C, Hjortkjaer RK, Pickersgill N, Virgo DM, Woolley AP. Glucagon produced by recombinant DNA technology: repeated dose toxicity studies, intravenous administration to CD rats and beagle dogs for four weeks. Pharmacol Toxicol. 1993;73:103\u20138.","journal-title":"Pharmacol Toxicol"},{"key":"26_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0169-409X(98)00054-4","volume":"36","author":"FW Merkus","year":"1999","unstructured":"Merkus FW, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PH, Hermens WA, et al. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev. 1999;36:41\u201357.","journal-title":"Adv Drug Deliv Rev"},{"key":"26_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0378-5173(02)00345-9","volume":"246","author":"K Asai","year":"2002","unstructured":"Asai K, Morishita M, Katsuta H, Hosoda S, Shinomiya K, Noro M, et al. The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. Int J Pharm. 2002;246:25\u201335.","journal-title":"Int J Pharm"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-015-0026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-015-0026-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-015-0026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,4]],"date-time":"2016-10-04T11:10:19Z","timestamp":1475579419000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-015-0026-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,26]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["26"],"URL":"https:\/\/doi.org\/10.1186\/s40360-015-0026-9","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,26]]},"article-number":"29"}}